De Lorenzo Ferruccio, Saba Neelam, Dancy Mark, Kakkar Vijay Vir, Kadziola Zbigniew, Xiao Han B
Thrombosis Research Institute, 1B Manresa Road, London SW3 6LR, UK.
Int J Cardiol. 2002 May;83(2):119-24. doi: 10.1016/s0167-5273(02)00029-3.
Most episodes of myocardial ischemia in patients with known coronary artery disease (CHD) are asymptomatic. Silent myocardial ischemia (SMI) is an important predictor of adverse outcome in patients with proven coronary artery disease. beta-blockers are effective in suppressing ischemia, and improve clinical outcome in patients with coronary artery disease. At present, it is common practice to stop treatment with beta-blockers in clinically asymptomatic patients after coronary artery bypass graft (CABG) and/or myocardial re-vascularization (PTCA/Stent), although the possible presence of SMI/inducible ischemia after myocardial re-vascularization is not known. We examined 56 asymptomatic CHD patients after coronary artery bypass graft (n=36), percutaneous coronary angioplasty PTCA/stent (n=15), or both (n=5); therapy with beta-blockers was stopped in all of them after myocardial revascularization. All these patients underwent a dobutamine stress echocardiography test (DSE test). The DSE test was proposed to these asymptomatic CHD patients to investigate the possible presence of SMI/inducible ischemia after myocardial re-vascularization. All patients had history of myocardial infarction or evidence of mildly impaired left ventricular function at rest as assessed by cardiac catheterization. Abnormal DSE studies occurred in eight of the 56 patients (14%; 95% C.I.: 6-26%). Therapeutic approaches specifically targeted at reducing total ischaemic burden include pharmacologic therapy and myocardial revascularization. On the basis of these data, it can be concluded that asymptomatic CHD patients after myocardial re-vascularization must be re-evaluated to rule out SMI/inducible ischemia that can be treated (e.g. with beta-blockers) reducing cardiovascular morbidity and mortality.
大多数已知患有冠状动脉疾病(CHD)的患者发生的心肌缺血发作是无症状的。无症状性心肌缺血(SMI)是已证实患有冠状动脉疾病患者不良预后的重要预测指标。β受体阻滞剂可有效抑制缺血,并改善冠状动脉疾病患者的临床结局。目前,临床上的常规做法是,在冠状动脉旁路移植术(CABG)和/或心肌血运重建术(PTCA/支架置入术)后,让无症状的患者停止使用β受体阻滞剂治疗,尽管心肌血运重建术后可能存在SMI/可诱导性缺血尚不清楚。我们检查了56例无症状的冠心病患者,这些患者接受了冠状动脉旁路移植术(n = 36)、经皮冠状动脉腔内血管成形术PTCA/支架置入术(n = 15)或两者都做了(n = 5);所有患者在心肌血运重建术后均停止了β受体阻滞剂治疗。所有这些患者都接受了多巴酚丁胺负荷超声心动图检查(DSE检查)。对这些无症状的冠心病患者进行DSE检查,以调查心肌血运重建术后是否可能存在SMI/可诱导性缺血。所有患者均有心肌梗死病史,或经心导管检查评估有静息时左心室功能轻度受损的证据。56例患者中有8例(14%;95%置信区间:6 - 26%)DSE检查结果异常。专门针对降低总缺血负荷的治疗方法包括药物治疗和心肌血运重建。基于这些数据,可以得出结论,心肌血运重建术后的无症状冠心病患者必须重新评估,以排除可治疗的SMI/可诱导性缺血(例如使用β受体阻滞剂),从而降低心血管疾病的发病率和死亡率。